Old | New | Differences | |
---|---|---|---|
1 | - | WES MOORE, Governor Ch. 849 | |
2 | 1 | ||
3 | - | – 1 – | |
4 | - | Chapter 849 | |
5 | - | (Senate Bill 408) | |
6 | 2 | ||
7 | - | AN ACT concerning | |
3 | + | EXPLANATION: CAPITALS INDICATE MAT TER ADDED TO EXISTIN G LAW. | |
4 | + | [Brackets] indicate matter deleted from existing law. | |
5 | + | Underlining indicates amendments to bill. | |
6 | + | Strike out indicates matter stricken from the bill by amendment or deleted from the law by | |
7 | + | amendment. | |
8 | + | *sb0408* | |
8 | 9 | ||
9 | - | Public Health – Maryland Department of Health – Reports on Standing Orders | |
10 | - | and Opioid Overdose Reversal Drugs – Standing Orders | |
10 | + | SENATE BILL 408 | |
11 | + | J1 4lr1762 | |
12 | + | CF HB 411 | |
13 | + | By: Senator Klausmeier | |
14 | + | Introduced and read first time: January 18, 2024 | |
15 | + | Assigned to: Finance | |
16 | + | Committee Report: Favorable with amendments | |
17 | + | Senate action: Adopted | |
18 | + | Read second time: March 16, 2024 | |
11 | 19 | ||
12 | - | FOR the purpose of requiring a licensed health care provider, when issuing a standing order | |
13 | - | for an opioid reversal drug, to allow an individual to choose any formulation of any | |
14 | - | opioid reversal drug approved by the federal Food and Drug Administration; | |
15 | - | requiring the Maryland Department of Health, on or before certain dates, to report | |
16 | - | to certain committees of the General Assembly on opioid overdose reversal drugs and | |
17 | - | standing orders; and generally relating to reports on standing orders for and opioid | |
18 | - | overdose reversal drugs. | |
20 | + | CHAPTER ______ | |
19 | 21 | ||
20 | - | BY repealing and reenacting, without amendments, | |
21 | - | Article – Health – General | |
22 | - | Section 13–3101(a) and (e) | |
23 | - | Annotated Code of Maryland | |
24 | - | (2023 Replacement Volume) | |
22 | + | AN ACT concerning 1 | |
25 | 23 | ||
26 | - | BY repealing and reenacting, with amendments, | |
27 | - | Article – Health – General | |
28 | - | Section 13–3106 | |
29 | - | Annotated Code of Maryland | |
30 | - | (2023 Replacement Volume) | |
24 | + | Public Health – Maryland Department of Health – Reports on Standing Orders 2 | |
25 | + | and Opioid Overdose Reversal Drugs – Standing Orders 3 | |
31 | 26 | ||
32 | - | SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, | |
33 | - | That the Laws of Maryland read as follows: on or before December 1, 2024, December 1, | |
34 | - | 2025, and December 1, 2026, the Maryland Department of Health shall report to the Senate | |
35 | - | Finance Committee and the House Health and Government Operations Committee, in | |
36 | - | accordance with § 2–1257 of the State Government Article, on: | |
27 | + | FOR the purpose of requiring a licensed health care provider, when issuing a standing order 4 | |
28 | + | for an opioid reversal drug, to allow an individual to choose any formulation of any 5 | |
29 | + | opioid reversal drug approved by the federal Food and Drug Administration; 6 | |
30 | + | requiring the Maryland Department of Health, on or before certain dates, to report 7 | |
31 | + | to certain committees of the General Assembly on opioid overdose reversal drugs and 8 | |
32 | + | standing orders; and generally relating to reports on standing orders for and opioid 9 | |
33 | + | overdose reversal drugs. 10 | |
37 | 34 | ||
38 | - | (1) current opioid overdose reversal drugs approved by the federal Food | |
39 | - | and Drug Administration; and | |
35 | + | BY repealing and reenacting, without amendments, 11 | |
36 | + | Article – Health – General 12 | |
37 | + | Section 13–3101(a) and (e) 13 | |
38 | + | Annotated Code of Maryland 14 | |
39 | + | (2023 Replacement Volume) 15 | |
40 | 40 | ||
41 | - | (2) for any current opioid overdose reversal drug approved by the federal | |
42 | - | Food and Drug Administration, whether the Department has added the drug to a standing | |
43 | - | order, and if not, the reasons why the drug has not been added. | |
41 | + | BY repealing and reenacting, with amendments, 16 | |
42 | + | Article – Health – General 17 | |
43 | + | Section 13–3106 18 | |
44 | + | Annotated Code of Maryland 19 | |
45 | + | (2023 Replacement Volume) 20 | |
44 | 46 | ||
45 | - | Article – Health – General | |
47 | + | SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, 21 | |
48 | + | That the Laws of Maryland read as follows: on or before December 1, 2024, December 1, 22 2 SENATE BILL 408 | |
46 | 49 | ||
47 | - | 13–3101. | |
48 | 50 | ||
49 | - | (a) In this subtitle the following words have the meanings indicated. Ch. 849 2024 LAWS OF MARYLAND | |
51 | + | 2025, and December 1, 2026, the Maryland Department of Health shall report to the Senate 1 | |
52 | + | Finance Committee and the House Health and Government Operations Committee, in 2 | |
53 | + | accordance with § 2–1257 of the State Government Article, on: 3 | |
50 | 54 | ||
51 | - | – 2 – | |
55 | + | (1) current opioid overdose reversal drugs approved by the federal Food 4 | |
56 | + | and Drug Administration; and 5 | |
52 | 57 | ||
53 | - | ( | |
54 | - | ||
55 | - | ||
58 | + | (2) for any current opioid overdose reversal drug approved by the federal 6 | |
59 | + | Food and Drug Administration, whether the Department has added the drug to a standing 7 | |
60 | + | order, and if not, the reasons why the drug has not been added. 8 | |
56 | 61 | ||
57 | - | ||
62 | + | Article – Health – General 9 | |
58 | 63 | ||
59 | - | (a) A licensed health care provider with prescribing authority may prescribe and | |
60 | - | dispense an opioid overdose reversal drug approved by the federal Food and Drug | |
61 | - | Administration to an individual who: | |
64 | + | 13–3101. 10 | |
62 | 65 | ||
63 | - | (1) Is believed by the licensed health care provider to be at risk of | |
64 | - | experiencing an opioid overdose; or | |
66 | + | (a) In this subtitle the following words have the meanings indicated. 11 | |
65 | 67 | ||
66 | - | (2) Is in a position to assist an individual at risk of experiencing an opioid | |
67 | - | overdose. | |
68 | + | (e) “Standing order” means a written instruction for the prescribing and 12 | |
69 | + | dispensing of an opioid overdose reversal drug approved by the federal Food and Drug 13 | |
70 | + | Administration in accordance with § 13–3106 of this subtitle. 14 | |
68 | 71 | ||
69 | - | (b) (1) A licensed health care provider with prescribing authority may | |
70 | - | prescribe and dispense opioid overdose reversal drugs approved by the federal Food and | |
71 | - | Drug Administration by issuing a standing order if the licensed health care provider: | |
72 | + | 13–3106. 15 | |
72 | 73 | ||
73 | - | (i) Is employed by the Department or a local health department; or | |
74 | + | (a) A licensed health care provider with prescribing authority may prescribe and 16 | |
75 | + | dispense an opioid overdose reversal drug approved by the federal Food and Drug 17 | |
76 | + | Administration to an individual who: 18 | |
74 | 77 | ||
75 | - | ( | |
76 | - | ||
78 | + | (1) Is believed by the licensed health care provider to be at risk of 19 | |
79 | + | experiencing an opioid overdose; or 20 | |
77 | 80 | ||
78 | - | (2) WHEN ISSUING A STANDI NG ORDER FOR AN OPIO ID REVERSAL | |
79 | - | DRUG UNDER PARAGRAPH (1) OF THIS SUBSECTION , A LICENSED HEALTH CA RE | |
80 | - | PROVIDER SHALL ALLOW THE INDIVIDUAL TO CH OOSE ANY FORMULATION OF ANY | |
81 | - | OPIOID REVERSAL DRUG APPROVED BY THE FEDE RAL FOOD AND DRUG | |
82 | - | ADMINISTRATION . | |
81 | + | (2) Is in a position to assist an individual at risk of experiencing an opioid 21 | |
82 | + | overdose. 22 | |
83 | 83 | ||
84 | - | [(2)] (3) A licensed health care provider with prescribing authority who | |
85 | - | issues a standing order under paragraph (1) of this subsection may delegate the dispensing | |
86 | - | of opioid overdose reversal drugs approved by the federal Food and Drug Administration to | |
87 | - | an employee or a volunteer of an authorized private or public entity in accordance with a | |
88 | - | written agreement under § 13–3104 of this subtitle. | |
84 | + | (b) (1) A licensed health care provider with prescribing authority may 23 | |
85 | + | prescribe and dispense opioid overdose reversal drugs approved by the federal Food and 24 | |
86 | + | Drug Administration by issuing a standing order if the licensed health care provider: 25 | |
89 | 87 | ||
90 | - | [(3)] (4) Any licensed health care provider who has dispensing authority | |
91 | - | also may dispense an opioid overdose reversal drug approved by the federal Food and Drug | |
92 | - | Administration to any individual in accordance with a standing order issued by a licensed | |
93 | - | health care provider with prescribing authority in accordance with this subsection. | |
94 | - | WES MOORE, Governor Ch. 849 | |
88 | + | (i) Is employed by the Department or a local health department; or 26 | |
95 | 89 | ||
96 | - | – 3 – | |
97 | - | (c) A pharmacist may dispense opioid overdose reversal drugs approved by the | |
98 | - | federal Food and Drug Administration in accordance with a therapy management contract | |
99 | - | under Title 12, Subtitle 6A of the Health Occupations Article. | |
90 | + | (ii) Has a written agreement with an authorized private or public 27 | |
91 | + | entity under § 13–3104 of this subtitle. 28 | |
100 | 92 | ||
101 | - | SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect | |
102 | - | October 1, 2024. | |
93 | + | (2) WHEN ISSUING A STANDI NG ORDER FOR AN OPIO ID REVERSAL 29 | |
94 | + | DRUG UNDER PARAGRAPH (1) OF THIS SUBSECTION , A LICENSED HEALTH CA RE 30 | |
95 | + | PROVIDER SHALL ALLOW THE INDIVIDUAL TO CH OOSE ANY FORMULATION OF ANY 31 | |
96 | + | OPIOID REVERSAL DRUG APPROVED BY THE FEDE RAL FOOD AND DRUG 32 | |
97 | + | ADMINISTRATION . 33 SENATE BILL 408 3 | |
103 | 98 | ||
104 | - | Approved by the Governor, May 16 , 2024. | |
99 | + | ||
100 | + | ||
101 | + | [(2)] (3) A licensed health care provider with prescribing authority who 1 | |
102 | + | issues a standing order under paragraph (1) of this subsection may delegate the dispensing 2 | |
103 | + | of opioid overdose reversal drugs approved by the federal Food and Drug Administration to 3 | |
104 | + | an employee or a volunteer of an authorized private or public entity in accordance with a 4 | |
105 | + | written agreement under § 13–3104 of this subtitle. 5 | |
106 | + | ||
107 | + | [(3)] (4) Any licensed health care provider who has dispensing authority 6 | |
108 | + | also may dispense an opioid overdose reversal drug approved by the federal Food and Drug 7 | |
109 | + | Administration to any individual in accordance with a standing order issued by a licensed 8 | |
110 | + | health care provider with prescribing authority in accordance with this subsection. 9 | |
111 | + | ||
112 | + | (c) A pharmacist may dispense opioid overdose reversal drugs approved by the 10 | |
113 | + | federal Food and Drug Administration in accordance with a therapy management contract 11 | |
114 | + | under Title 12, Subtitle 6A of the Health Occupations Article. 12 | |
115 | + | ||
116 | + | SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect 13 | |
117 | + | October 1, 2024. 14 | |
118 | + | ||
119 | + | ||
120 | + | ||
121 | + | Approved: | |
122 | + | ________________________________________________________________________________ | |
123 | + | Governor. | |
124 | + | ________________________________________________________________________________ | |
125 | + | President of the Senate. | |
126 | + | ________________________________________________________________________________ | |
127 | + | Speaker of the House of Delegates. |